Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.20.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating expenses:    
Research and development $ 1,381 $ 2,607
General and administrative 1,023 814
Operating loss (2,404) (3,421)
Other (income) expense:    
Governmental assistance - research incentives (115) (174)
Other (income) expense, net 127 (4)
Total other (income) expense 12 (178)
Loss before income tax expense (2,416) (3,243)
Income tax expense 9 9
Net loss (2,425) (3,252)
Other comprehensive income    
Unrealized gain on marketable securities 40 3
Net loss and comprehensive loss $ (2,385) $ (3,249)
Basic and diluted net loss per share (in dollars per share) $ (0.19) $ (0.27)
Weighted average shares outstanding – basic and diluted (in shares) 13,107,725 11,956,874